VolitionRx: Andrew Retter

VolitionRx has appointed Andrew Retter as its chief medical officer, effective April 1. He is an intensive care consultant at Guy's and St. Thomas' NHS Foundation Trust in London, where he leads clinical governance in critical care. A specialist in managing severe respiratory failure, extracorporeal membrane oxygenation, and thrombosis, Retter has advised VolitionRx since January 2022 in the development of the company's NuQ NET, a blood-based test for detecting diseases associated with NETosis, a form of cell death, including sepsis.